Maker of OxyContin Now Has a Plan to Profit Off the Opioid Crisis They Had a Hand In Creating

PHILADELPHIA, PA - JANUARY 24: A man uses heroin under a bridge where he lives with other addicts in the Kensington section of Philadelphia which has become a hub for heroin use on January 24, 2018 in Philadelphia, Pennsylvania. Over 900 people died in 2016 in Philadelphia from opioid overdoses, a 30 percent increase from 2015. As the epidemic shows no signs of weakening, the number of fatalities this year is expected to surpass last year's numbers. Heroin use has doubled across the country since 2010, according to the DEA, part of an epidemic. Officials from Philadelphia recently announced that they want to become the first U.S. city to allow supervised drug injection sites as a way to combat the opioid epidemic. (Photo by Spencer Platt/Getty Images)

In a twist completely apropos for 2018, Purdue Pharma, the maker of OxyContin, has received a patent for a medication designed to treat opioid addiction. Purdue Pharma is largely considered to be responsible for the current opioid epidemic.

The patent is not for an entirely new medication; rather, it is for a new and fast-acting form of an existing medication: buprenorphine.


One popular form of buprenorphine is sold under the name Suboxone. The medication acts as an opioid replacement. It works by controlling drug cravings and is used as an alternative for individuals hooked on painkillers or heroin. The current method of transmission for buprenorphine is a sublingual strip or tablet that dissolves under the tongue — something that can take up to 15 minutes to dissolve. The new form would be given in wafer form, dissolving in just a matter of seconds.

"While opioids have always been known to be useful in pain treatment, they also display an addictive potential. Thus, if opioids are taken by healthy human subjects with a drug-seeking behaviour they may lead to psychological as well as physical dependence,” the patent states.

OxyContin was originally created in 1995 by Purdue Pharma, and heavily marketed as a miracle painkiller. The marketing campaign was aggressive and eventually led to OxyContin becoming the most widely prescribed opioid medication. Even though sales have declined in recent years, the company still grossed over $2 billion in sales from the medication.

PHILADELPHIA, PA - JANUARY 24: A man uses heroin under a bridge where he lives with other addicts in the Kensington section of Philadelphia which has become a hub for heroin use on January 24, 2018 in Philadelphia, Pennsylvania. Over 900 people died in 2016 in Philadelphia from opioid overdoses, a 30 percent increase from 2015. As the epidemic shows no signs of weakening, the number of fatalities this year is expected to surpass last year's numbers. Heroin use has doubled across the country since 2010, according to the DEA, part of an epidemic. Officials from Philadelphia recently announced that they want to become the first U.S. city to allow supervised drug injection sites as a way to combat the opioid epidemic. (Photo by Spencer Platt/Getty Images)

In recent years, Purdue Pharma has been associated with numerous lawsuits related to the opioid epidemic. The Sackler family, which controls Purdue, was personally named in one of the lawsuits this past June. The Massachusetts Attorney General accused the family of a “deadly, deceptive scheme to sell opioids.”

For the most part, Purdue Pharma denies any culpability and deceptive practices. In a statement to CBS News, the company stated that all of their practices have been above board.

"Purdue is confident that its past marketing and sales of its prescription opioid medications have been consistent with the information contained in the FDA-approved label as the agency oversees the risks and benefits of prescription medications. Additionally, FDA has, and continues to, rigorously assess the science and medical practice around the appropriate treatment of chronic pain, while simultaneously working hard to ensure that our society suffers less from the scourges of prescription opioid abuse and addiction. Purdue is committed to working collaboratively with all those impacted by this public health crisis to help stem the tide of opioid-related deaths and addiction."

More than 72,000 people died from drug overdoses in 2017. That death count is higher than the yearly death tolls from HIV, car crashes or gun deaths. According to the CDC, 48,000 people died from opioid-related overdoses in the last year. Since 2013, 170,000 opioid-related deaths have occurred. The death toll, as caused by opioids, is staggering and epidemic. It’s tremendously ironic that a company largely credited for contributing to the addiction epidemic would now want to profit from its treatment.

As that death toll related to overdose and addiction continues to rise, something needs to be done on a systemic level. We need a solution based on new health initiatives, public health, and stigmatization, rather than allow the company which largely created the problem to continue to profit from it.

Melina Mara/The Washington Post via Getty Images

The Senate undertook one of the gravest American political processes on Tuesday when the impeachment trial against President Donald Trump began in earnest as House Managers and Trump's defense team debated to set the rules for the ensuing trial.

On Wednesday, the Democratic impeachment managers began their 24 allotted hours (set over the course of three days) to make their case against Trump. They've cited documents, videos, and Trump's own words to create a compelling case for the removal of the President—or at least for hearing the evidence he's repeatedly blocked from coming to light.

But are Republican Senators listening?

Keep reading...
C-SPAN

Late last year, the House of Representatives voted to impeach President Donald Trump on two articles:

  • Abuse of Power
  • Obstruction of Congress

Trump's allies have railed against both articles, but the obstruction of Congress charge has come under particular focus.

During its initial investigation, the House committees overseeing impeachment requested documents and witnesses from the White House, the State Department, and the Office of Management and Budget that would help get to the bottom of just what the deal was with Ukraine's foreign policy.

When they denied the House's request, the House subpoenaed the departments for the evidence. Claiming executive privilege, their subpoenas went ignored.

Keep reading...
CNN // David Corio/Redferns via Getty Images

House Impeachment Managers and President Donald Trump's defense team debated the rules for the ongoing impeachment trial in the Senate. The proceedings lasted for 13 hours and went on until around 2 o'clock in the morning.

Hours into the debate, Congressman Hakeem Jeffries (D-NY) responded to a rhetorical question from Trump attorney Jay Sekulow, who had asked "Why are we here?"

It led to a mic drop moment for Jeffries.

Keep reading...
Chip Somodevilla/Getty Images

This past December, the House Judiciary Committee held a hearing where it heard from constitutional scholars and legal experts as to whether President Donald Trump's pressure on Ukraine to open politically beneficial investigations warranted impeachment.

House Democrats brought forth three witnesses who argued in favor of impeachment, and House Republicans brought one: George Washington University's public interest law chair, Jonathan Turley.

Keep reading...
PBS News Hour/YouTube

The White House Counsel is a staff appointee of the President and Vice President of the United States. Their role is to advise the President on all legal issues concerning the President and their administration.

Pat Cipollone has served as the current White House Counsel for President Donald Trump since December 2018.

Keep reading...
SAUL LOEB/AFP via Getty Images

In the current political landscape of the United States, you'd be hard-pressed to find any issue that Americans on which both sides of the ideological spectrum agree.

But it turns out that even on an issue as divisive as the impeachment of President Donald Trump, Republicans and Democrats agree on something.

Keep reading...